Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

CELONTIN 300 MG CAPSULE

methsuximide
$4.3993per EA

Strength

300 mg/1

Manufacturer

Pfizer Inc.

NDC

00071052524

Classification

Brand

Dosage Form

CAPSULE

Route

ORAL

Last Updated

1/1/2025

Active Ingredients

METHSUXIMIDE

Approval Type

New Drug (NDA)

FDA Application

NDA010596

On Market Since

2/8/1957

Pharmacological Classes

Anti-epileptic Agent
Decreased Central Nervous System Disorganized Electrical Activity

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

0.0%

1Y

0.0%

3Y

+7.5%

5Y

+7.5%

All

+124.5%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Related Drugs

Same classification

TEGRETOL 100 MG/5 ML SUSP
Brand
00078050883•Novartis Pharmaceuticals Corporation
$0.4379
per ML
ZARONTIN 250 MG CAPSULE
Brand
00071023724•Pfizer Inc.
$1.3086
per EA
EPRONTIA 25 MG/ML SOLUTION
Brand
52652900101•Azurity Pharmaceuticals Inc.
$1.6041
per ML
TEGRETOL XR 100 MG TABLET
Brand
00078051005•Novartis Pharmaceuticals Corporation
$1.6345
per EA
CARBATROL ER 200 MG CAPSULE
Brand
54092017212•Takeda Pharmaceuticals America, Inc.
$1.6917
per EA
CARBATROL ER 300 MG CAPSULE
Brand
54092017312•Takeda Pharmaceuticals America, Inc.
$1.6963
per EA
CARBATROL ER 100 MG CAPSULE
Brand
54092017112•Takeda Pharmaceuticals America, Inc.
$1.7005
per EA
KEPPRA 100 MG/ML ORAL SOLN
Brand
50474000148•UCB, Inc.
$1.9234
per ML
TRILEPTAL 300 MG/5 ML SUSP
Brand
00078035752•Novartis Pharmaceuticals Corporation
$1.9345
per ML
DEPAKOTE DR 125 MG SPRINKLE CP
Brand
00074611413•AbbVie Inc.
$1.9719
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy